Ollayos C W, Riordan G P, Rushin J M
Department of Laboratory Medicine, National Naval Medical Center, Bethesda, MD.
Arch Pathol Lab Med. 1994 Jun;118(6):630-2.
We performed a retrospective analysis for the presence of estrogen receptors (ERs) in known cases of adenocarcinoma of the colon, pancreas, and lung. Estrogen receptor status was determined by immunohistochemical methods using the ER-ICA (Abbott Laboratories, North Chicago, Ill) antibody on paraffin sections. None of 43 colon and 18 pancreatic adenocarcinomas demonstrated ERs by this method. Three of 42 lung adenocarcinomas exhibited some degree of nuclear staining for ERs. When evaluating an adenocarcinoma of unknown primary site, the ER-ICA antibody can be useful when included in a panel of antibodies. Positive results tend to exclude colonic or pancreatic, but not pulmonary, primary sites.
我们对已知的结肠、胰腺和肺癌腺癌病例中雌激素受体(ERs)的存在情况进行了回顾性分析。雌激素受体状态通过免疫组织化学方法,使用ER-ICA(雅培实验室,伊利诺伊州北芝加哥)抗体在石蜡切片上进行测定。通过这种方法,43例结肠腺癌和18例胰腺腺癌均未显示出雌激素受体。42例肺腺癌中有3例表现出一定程度的雌激素受体核染色。在评估原发部位不明的腺癌时,将ER-ICA抗体纳入一组抗体中可能会有所帮助。阳性结果往往排除结肠或胰腺的原发部位,但不能排除肺部的原发部位。